marketshareAI

Scancell Holdings

SCLPHealthcare
10.00GBX
2.56%
Market Cap
104.20M
Volume
3.82k
1% of avg
P/E Ratio
-0.07
EPS (TTM)
-1.53
Beta
-0.09
Day Range
0.00p - 0.00p
52 Week Range
0.00p10.00p19.75p
10.00p

Upcoming Events

Mid 2025
Clinical data from SCIB1 in cohort 1 and iSCIB1+ in cohort 3 expected
High Impact Event
H2 2025
Expected early data for Modi-1 in renal cell carcinoma with double CPIs cohort
High Impact Event
Late 2025
Clinical data from iSCIB1+ in cohort 4, following the partnership with CVLP, expected
High Impact Event
H2 2026
Planned randomised trial, either by Scancell or in partnership
High Impact Event
SCLP
NEUTRAL

Scancell Partners with NHS Cancer Vaccine Launch Pad to Accelerate Melanoma Vaccine Trial

The biotechnology company has partnered with the NHS to accelerate patient access to its cancer vaccine trial for advanced melanoma patients.

SCLP
NEUTRAL

Scancell to Present SCIB1 Cancer Vaccine Data at AACR 2025

The biopharmaceutical company will present clinical data from the ongoing Phase 2 SCOPE trial of its SCIB1 cancer vaccine at the 2025 AACR Annual Meeting.

SCLP
NEUTRAL

Scancell grants share options to executives

The biopharmaceutical company has granted share options to its executive team, aligning their interests with long-term shareholder value.

SCLP
NEUTRAL

Scancell to present SCOPE trial data at AACR IO conference

The biotechnology company will present translational data from the Phase 2 SCOPE trial of its cancer vaccine SCIB1 at the upcoming AACR IO conference.

SCLP
NEUTRAL

Scancell Reports Strong Clinical Progress in Interim Results

The clinical-stage biopharmaceutical company reported strong progress in key cancer vaccine trials, alongside increased R&D spending and operating losses. Recent fundraising extends the cash runway for continued development.

SCLP
NEUTRAL

Scancell to Announce Interim Results

Clinical-stage biotech company to report interim results

SCLP
GOOD

Scancell's Modi-1 Vaccine Achieves Early Clinical Validation in Head and Neck Cancer

The biopharmaceutical company's lead vaccine candidate achieved promising early clinical results in head and neck cancer, setting the stage for further development.

SCLP
BAD

Scancell secures £10.3M in oversubscribed placing

Biotech firm raises funds for cancer vaccine development

SCLP
BAD

Scancell Announces £9 Million Capital Raise

Biotech firm seeks £9M in discounted offer

SCLP
BAD

Scancell Announces £8.5 Million Fundraise to Advance Cancer Vaccine Trials

Biotech firm seeks funds for cancer vaccine trials